$1,255.40▲ 11.00 (0.88%)
Real-time prices · US MarketsEarnings growing 26% year-over-year on 48% revenue growth.
Quality
9
Health
5.5
Growth
9.8
Valuation
5.8
Sentiment
7.9
Analyst Target
$1315.04
▲ +4.8% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
42.2×
price-to-earnings
Forward P/E
26.6×
next 12 months est.
Market Cap
$1.12T
market capitalization
Div Yield
0.55%
dividend yield
Profit Margin
33.5%
net profit margin
Gross Margin
83.4%
revenue minus COGS
ROE
102.3%
return on equity
Beta
0.51
vs S&P 500
52-Week Range
$694 — $1,293
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Eli Lilly and Company right now?
Eli Lilly and Company's Q·Score is 7.7/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Earnings growing 26% year-over-year on 48% revenue growth. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for LLY?
The consensus price target for LLY is $1315.04, based on ratings from 29 Wall Street analysts. This is 4.8% above the current price of $1255.40. Price targets are forward-looking estimates and not guarantees of future performance.
Is LLY overvalued or undervalued?
Eli Lilly and Company (LLY) scores in line with sector averages on valuation metrics. Its forward P/E ratio stands at 26.6×.
When does Eli Lilly and Company report its next earnings?
Eli Lilly and Company's next earnings report is expected on approximately October 29, 2026.
What is Eli Lilly and Company's profit margin?
Eli Lilly and Company has a net profit margin of 33.5%, which is considered high and reflects strong pricing power. Its gross margin stands at 83.4%, indicating a high-margin business model.
What is LLY's dividend yield?
Eli Lilly and Company currently offers a dividend yield of 0.55%, a modest payout typical for growth-oriented companies. Dividend yields can change based on price movements and company payout decisions.
Is Eli Lilly and Company's revenue growing?
Eli Lilly and Company is reporting strong year-over-year growth of 47.7%. Earnings are also growing at 26.2%, indicating improving profitability.
How much debt does Eli Lilly and Company have?
Eli Lilly and Company has a debt-to-equity ratio of 1.62×, reflecting a moderately high debt load — watch cash flow coverage. Its current ratio is 1.35×, suggesting it should be monitored for near-term liquidity.